Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Monza – page 206

2 831 clinical trials in Monza, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Monza at a glance
2 831
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

2 831 trials in Monza

Open in trial search

Plasma cell myeloma

Not recruiting

Study of Durbactagene Autoleucel and Drug Combination for Adults with Relapsed and Refractory Multiple Myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bendamustine
  • Sponsor:Novartis Pharma AG

Warm autoimmune haemolytic anaemia

Not recruiting

Study of ianalumab versus placebo in adults with warm autoimmune hemolytic anemia who failed previous treatment

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Danazol
  • Sponsor:Novartis Pharma AG

Hepatocellular carcinoma

Not recruiting

Study on Durvalumab and Tremelimumab for Patients with Advanced Liver Cancer Not Treatable by Surgery

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Astrazeneca AB

Endometrial cancer stage III+1

Not recruiting

Study on Dostarlimab, Carboplatin, and Paclitaxel for Patients with Recurrent or Advanced Endometrial Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Tesaro Inc.

Bladder cancer

Not recruiting

Study on Durvalumab, Tremelimumab, and Enfortumab Vedotin for Patients with Muscle Invasive Bladder Cancer Ineligible or Refusing Cisplatin

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Astrazeneca AB

Gastroenteropancreatic neuroendocrine tumour disease

Not recruiting

Study of Lutetium (177Lu) Edotreotide compared to standard treatment in patients with aggressive Grade 2 and Grade 3 gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:ITM Solucin GmbH

Immune thrombocytopenia

Not recruiting

Study Comparing Romiplostim and Dexamethasone with Dexamethasone Alone for Patients with Newly Diagnosed Primary Immune Thrombocytopenia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Romiplostim
  • Sponsor:Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla

Actinic keratosis

Not recruiting

Study on the Safety of Tirbanibulin and Diclofenac Sodium for Adults with Actinic Keratosis on the Face or Scalp

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Diclofenac Sodium
  • Sponsor:Almirall S.A.

Breast cancer+1

Not recruiting

Study of ribociclib combined with hormone therapy for patients with early-stage hormone receptor-positive, HER2-negative breast cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Novartis Pharma AG

Endocrine ophthalmopathy

Not recruiting

Study on Batoclimab for Patients with Thyroid Eye Disease

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Batoclimab
  • Sponsor:Immunovant Sciences GmbH

Age-related macular degeneration

Not recruiting

Study on the Effectiveness and Safety of Ranibizumab for Patients with Wet Age-Related Macular Degeneration Using a 36-Week Refill System

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Ranibizumab
  • Sponsor:F. Hoffmann-La Roche AG

Glioma

Not recruiting

Study of Vorasidenib for Patients with Residual or Recurrent Grade 2 Glioma with IDH1 or IDH2 Mutation

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Vorasidenib
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Monza

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on lung cancer treatments and novel approaches for lymphoma management. Studies include targeted therapies and immunotherapy combinations.

  • NSCLC Treatment Studies
  • Lymphoma Therapy Innovations
  • Breast Cancer Research

Advanced investigations into personalized treatment approaches for various cancer types using targeted therapies and immunological interventions.

02 Autoimmune Conditions

Research focusing on psoriatic arthritis and multiple sclerosis, evaluating novel biological treatments and their effectiveness in managing disease progression.

  • Inflammatory Disease Studies
  • Biomarker Research
  • Treatment Response Evaluation

Comprehensive studies examining new therapeutic approaches for chronic autoimmune conditions.

03 Infectious Diseases

Vaccine development studies targeting Herpes Zoster and Cytomegalovirus, focusing on prevention and immune response in different age groups.

  • Vaccine Efficacy Studies
  • Long-term Immunity Research
  • Viral Prevention Strategies

Advanced clinical trials evaluating new vaccination approaches and therapeutic strategies.

04 Cardiovascular Studies

Innovative research on heart failure prevention and pulmonary arterial hypertension, testing new therapeutic combinations and treatment approaches.

  • Preventive Cardiology
  • Hypertension Management
  • Drug Combination Studies

Investigation of novel therapeutic strategies for cardiovascular disease management and prevention.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease? Our clinical trial advisor will do it for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.